$IBIO I have hard time seeing NVAX/Fuji/TAMU collaboration as a blow to IBIO.. My understanding is that IBIO is currently working with TAMU for a pre-clinical study. If the results are good (which look that way), IBIO can move onto human trials (and work with whoever IBIO wants to for those, not just TAMU), and produce its own vaccines at that point. Funding will likely come IBIO's way after the pre-clinical results are officially out (no complaints whatsoever if funding comes first though).
  • 6